Navigation Links
Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010
Date:6/26/2010

ORLANDO, Fla., June 26, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from a study comparing the effect of long-term treatment with either BYETTA® (exenatide) injection or Lantus® (insulin glargine) on overall beta-cell function. (Beta cells are cells in the pancreas that produce insulin.) Three years of BYETTA therapy improved indices of beta-cell function assessed four weeks after discontinuing therapy. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) in Orlando, Fla.

After three years of treatment, both therapies reduced A1C similarly (by 0.7 percentage points to 6.6 percent for BYETTA and by 0.5 percentage points to 6.9 percent for Lantus). A1C is a measure of average blood sugar over three months. In addition, BYETTA significantly reduced body weight compared to Lantus (17-pound difference between groups). After completion of three years of therapy, a four-week off-drug period followed to allow assessment of parameters of metabolic state including beta-cell function. Beta-cell function was assessed using a calculated disposition index (insulin secretion adjusted for insulin sensitivity). BYETTA increased insulin sensitivity by 39 percent and increased the disposition index, indicating an improvement in background beta-cell function. Lantus had no effect on insulin sensitivity or disposition index.

"Type 2 diabetes is a progressive disease in which insulin production typically decreases over time," said '/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Study Data Show INTUNIV™ (guanfacine) Extended Release Tablets Co-administered With Stimulants Provided ADHD Symptom Improvement in Children and Adolescents
2. Renhuang Pharmaceuticals Announces Continual Improvement in Days Sales Outstanding
3. Garnet BioTherapeutics Announces First Patient Treated in Trial of New Therapy for Improvement in Scar Appearance
4. PARI Pharmas Altera Delivers Gileads Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa
5. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
6. AstraZeneca Offers Online Enrollment and Additional Improvements to Patient Assistance Program
7. Solos Endoscopy, Inc. Makes Significant Design Improvement To Its MammoView(TM) Ductoscope
8. NQF Helps Ensure Health IT Captures Information to Drive Quality Improvement
9. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
10. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
11. Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Calif. , July 29, 2015 Sangamo ... the company will release its second quarter 2015 financial ... 2015. The press release will be followed by a ... open to the public via telephone and webcast. During ... financial results and discuss other business matters. ...
(Date:7/29/2015)... 29, 2015 Alvarado Hospital unveiled its ... Alvarado Spine & Joint Institute. The institute is ... on spinal surgery and joint replacement. The Spine ... a patient experience-focused approach. For example, patients are ... in, rather than patient gowns. ...
(Date:7/29/2015)... July 29, 2015   Turing Pharmaceuticals AG ... joined the company as its first Chief Communication Officer. ... have overall responsibility for internal and external communications and ... He will report directly to Founder and Chairman, ... Leadership Team. "We are excited to have ...
Breaking Medicine Technology:Sangamo BioSciences Announces Second Quarter 2015 Conference Call and Webcast 2The Alvarado Spine & Joint Institute Opens July 30 in San Diego 2Turing Pharmaceuticals Names Craig Rothenberg Chief Communication Officer 2Turing Pharmaceuticals Names Craig Rothenberg Chief Communication Officer 3
... 8 Nektar,Therapeutics (Nasdaq: NKTR ) today ... program to evaluate NKTR-102 (PEG-irinotecan) as a,potential treatment ... using the company,s innovative small molecule,PEGylation technology platform., ... for NKTR-102 in colorectal cancer is,a major achievement ...
... Trial Data and Emerging Clinical Practice Experience Support ... HYLENEX Efficacy ... Therapeutics, Inc.,(Nasdaq: HALO ), a biopharmaceutical company developing and ... publication of the INFUSE-LR clinical trial results in the Journal,of ...
Cached Medicine Technology:Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer 2Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer 3Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer 4Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 2Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 3Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 4Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 5
(Date:7/29/2015)... ... 2015 , ... Abt Associates has named Selena Ramkeesoon, a ... In her position, Ramkeesoon will help build and expand work in communications, and ... to a decade at ICF International, most recently as a vice president. During ...
(Date:7/29/2015)... ... July 29, 2015 , ... According to the The Media ... and are exposed to advertisements, for medicinal use are more likely to abuse the ... the use of marijuana is considered beneficial are more apt to use the substance, ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... the therapeutic development for Atherosclerosis. Atherosclerosis is a slow, progressive disease that may ... MOAs to produce first-in-class and best-in-class products. Complete report on Atherosclerosis Pipeline with ...
(Date:7/29/2015)... ... 29, 2015 , ... The NCCA re-accredited the Commission for ... 30, 2019, during its recent meeting. , The Commission received renewal of NCCA ... with the NCCA’s Standards for the Accreditation of Certification Programs. NCCA is ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... Michigan, changed its name in July to Kalamazoo Strength & Conditioning. , The ... , and “reflects the evolution of our training center over the past three ...
Breaking Medicine News(10 mins):Health News:Selena Ramkeesoon Joins Abt Associates as Vice President for Strategic Communications 2Health News:New Study Reveals Teens Use Marijuana More in States Where Marijuana Is Legalized 2Health News:New Study Reveals Teens Use Marijuana More in States Where Marijuana Is Legalized 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 2Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 2Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 4
... study has shown that those people who eat breakfast regularly ... The researchers found from the Children’s Hospital in Boston that ... per cent lower among people who ate breakfast compared to ... Insulin resistance syndrome is a disorder that includes// obesity, high ...
... reported by researchers in the Journal of Hypertension ... morbidity and improve their atherosclerotic risk profile by ... indicated that serum lipoprotein(a), a powerful predictor of ... The researchers studied 402 patients with untreated essential ...
... now much easier than earlier and according to James ... many people, both men and women are seeing plastic ... past, when patients would wait until they were 50 ... signs of aging. He also added that non-surgical treatments ...
... Drug Administration's(FDA) new effort to re-examine very old ... required proof that drugs worked well, has landed ... trouble. Until now FDA stressed that the expectorant, ... crackdown lead to the FDA formally approving sale ...
... Institute, led by Glenn Dranoff, MD,have reported in the ... vaccines made from patients' own tumors are safe and ... for deadly cancers. Researchers claim that the tumors grow ... immune system attacks -- ignore them. In the new ...
... for Preventing and Reversing Atherosclerosis in Houston, Texas, ... that intense lifestyle changes plus pharmacologic lipid treatment ... a greater extent than usual-care cholesterol lowering drugs. ... by performing myocardial perfusion imaging at baseline and ...
Cached Medicine News:Health News:New lung cancer vaccine on the anvil 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: